Table 3 The International Metastatic Renal-Cell Carcinoma Database Consortium Model for prognosis in first-line treatment for metastatic RCC (Heng et al, 2013)

From: Medical treatment of renal cancer: new horizons

Criteria

Karnofsky performance status <80%

Time from diagnosis to treatments <1 year

Hb<LLN

Corrected calcium >ULN

Neutrophils>ULN

Platelets>ULN

Number of criteria

Group

Median overall survival

0

Favourable

43.2 months (95% CI 31.4–50.1)

1–2

Intermediate

33.5 months (95% CI 18.7–25.1)

3–6

Poor

7.8 months (95% CI 6.5–9.7)

  1. Abbreviations: LLN=lower limit of normal; ULN=upper limit of normal.
Back to article page